Our clinical program for relugolix combination tablet* consists of three international Phase 3 clinical trials, two in women with endometriosis-associated pain (SPIRIT 1 & 2) and one for the prevention of pregnancy (SERENE).
We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential trigger of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).
*tablet is the intended commercial presentation based on pharmaco-equivalence data with relugolix combination therapy (co-administration of relugolix 40 mg with estradiol 1.0 mg and norethindrone acetate 0.5 mg)
MYFEMBREE® (relugolix, estradiol, and norethindrone acetate)
A study evaluating relugolix combination tablet for the management of moderate to severe pain associated with endometriosis.
A study evaluating relugolix combination tablet in women with endometriosis or uterine fibroids for the prevention of pregnancy.
A study evaluating MVT-602 in female infertility as part of assisted reproduction.
Learn more about our clinical trials
We cannot achieve our mission to redefine care for women and for men without clinical trials. All across the world, patients, families, physicians, and clinics support these trials as we strive to turn our purpose-driven science into empowering medicines.
10 May 2022
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
9 May 2022
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
6 May 2022
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
29 Apr 2022
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
26 Apr 2022
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022